Dr. Minesh Mehta Talks About A Newly-Approved Device To Treat Glioblastoma
Minesh Mehta, MBChB, talks about the recently FDA-approved Optune used to treat newly diagnosed glioblastoma. The device utilizes alternating electric fields to inhibit tumor cell growth.
Minesh Mehta, MBChB, medical director, Maryland Proton Treatment Center, talks about Optune, the recently FDA-approved device used to treat newly diagnosed glioblastoma. The system utilizes alternating electric fields to inhibit tumor cell growth.
Mehta says that he hopes the device will become more widespread in the future after more research comes out about its clinical benefit.
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
